X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (306) 306
razoxane - therapeutic use (243) 243
female (174) 174
male (129) 129
oncology (120) 120
adult (110) 110
razoxane - adverse effects (106) 106
antibiotics, antineoplastic - adverse effects (98) 98
doxorubicin - adverse effects (91) 91
razoxane - administration & dosage (89) 89
animals (83) 83
middle aged (83) 83
antineoplastic agents - adverse effects (79) 79
cardiovascular agents - therapeutic use (78) 78
heart - drug effects (77) 77
aged (74) 74
anthracyclines - adverse effects (69) 69
dexrazoxane (68) 68
doxorubicin (67) 67
child (61) 61
razoxane - pharmacology (59) 59
cardiotoxicity (57) 57
neoplasms - drug therapy (53) 53
heart diseases - chemically induced (52) 52
heart diseases - prevention & control (52) 52
breast neoplasms - drug therapy (51) 51
piperazines - therapeutic use (51) 51
chemotherapy (48) 48
adolescent (47) 47
clinical trials as topic (46) 46
advanced breast-cancer (44) 44
index medicus (44) 44
risk factors (43) 43
antineoplastic agents - therapeutic use (42) 42
anthracyclines (41) 41
cardiomyopathies - chemically induced (41) 41
doxorubicin - administration & dosage (41) 41
icrf-187 (40) 40
pharmacology & pharmacy (38) 38
antineoplastic combined chemotherapy protocols - adverse effects (36) 36
cardiomyopathies - prevention & control (36) 36
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
rats (34) 34
treatment outcome (34) 34
dose-response relationship, drug (32) 32
antibiotics, antineoplastic - administration & dosage (31) 31
cancer (31) 31
chelating agents - therapeutic use (29) 29
razoxane (29) 29
time factors (29) 29
anthracycline (28) 28
mice (27) 27
adriamycin (26) 26
child, preschool (26) 26
anthracyclines - administration & dosage (25) 25
cardiac toxicity (25) 25
cardiomyopathy (25) 25
drug administration schedule (25) 25
drug evaluation (25) 25
antibiotics, antineoplastic - therapeutic use (24) 24
heart failure - chemically induced (24) 24
toxicity (24) 24
acute lymphoblastic-leukemia (23) 23
doxorubicin - therapeutic use (23) 23
extravasation of diagnostic and therapeutic materials - drug therapy (23) 23
prevention (23) 23
drug therapy, combination (22) 22
antineoplastic agents - administration & dosage (21) 21
cardiotonic agents - therapeutic use (21) 21
heart failure - prevention & control (21) 21
cardiovascular agents - administration & dosage (20) 20
echocardiography (20) 20
cardioprotection (19) 19
cardiovascular agents - pharmacology (19) 19
doxorubicin-containing therapy (19) 19
epirubicin - adverse effects (19) 19
children (18) 18
cyclophosphamide - administration & dosage (18) 18
fluorouracil - administration & dosage (18) 18
psoriasis - drug therapy (18) 18
epirubicin (17) 17
hematology (17) 17
randomized controlled trials as topic (17) 17
women (17) 17
anthracyclines - therapeutic use (16) 16
breast cancer (16) 16
cyclophosphamide - adverse effects (16) 16
piperazines - adverse effects (16) 16
retrospective studies (16) 16
risk-factors (16) 16
childhood-cancer (15) 15
fluorouracil - adverse effects (15) 15
neoplasm metastasis (15) 15
prospective studies (15) 15
rectal neoplasms - drug therapy (15) 15
therapy (15) 15
ventricular function, left - drug effects (15) 15
breast neoplasms - pathology (14) 14
colonic neoplasms - drug therapy (14) 14
epirubicin - administration & dosage (14) 14
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (316) 316
Russian (12) 12
German (7) 7
Chinese (5) 5
Italian (5) 5
Polish (5) 5
Czech (4) 4
French (2) 2
Hungarian (2) 2
Dutch (1) 1
Japanese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Antioxidants & Redox Signaling, ISSN 1523-0864, 03/2013, Volume 18, Issue 8, pp. 899 - 929
Significance: Anthracyclines (doxorubicin, daunorubicin, or epirubicin) rank among the most effective anticancer drugs, but their clinical usefulness is... 
Forum Review Articles | DOXORUBICIN-INDUCED CARDIOTOXICITY | ADVANCED BREAST-CANCER | SPONTANEOUSLY HYPERTENSIVE-RATS | MANGANESE SUPEROXIDE-DISMUTASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | ADRIAMYCIN-INDUCED CARDIOMYOPATHY | ACUTE LYMPHOBLASTIC-LEUKEMIA | ENDOCRINOLOGY & METABOLISM | SALICYLALDEHYDE ISONICOTINOYL HYDRAZONE | MITOCHONDRIAL CALCIUM HOMEOSTASIS | CONGESTIVE-HEART-FAILURE | FREE-RADICAL FORMATION | Anthracyclines - adverse effects | Reactive Oxygen Species - metabolism | Antioxidants - chemistry | Oxidative Stress | Humans | Metals - adverse effects | Razoxane - pharmacology | Anthracyclines - pharmacology | Antineoplastic Agents - adverse effects | Cardiotonic Agents - adverse effects | Myocardium - metabolism | Antineoplastic Agents - pharmacology | Razoxane - chemistry | Chelating Agents - adverse effects | Anthracyclines - chemistry | Oxidation-Reduction | Signal Transduction | Chelating Agents - chemistry | Cardiotonic Agents - chemistry | Antioxidants - pharmacology | Cardiotonic Agents - pharmacology | Chelating Agents - pharmacology | Antineoplastic Agents - chemistry | Razoxane - adverse effects | Heart - drug effects | Complications and side effects | Oxidative stress | Anthracyclines | Oxidation-reduction reaction | Chemical reactions | Dosage and administration | Research | Index Medicus | Forum Review
Journal Article
Circulation, ISSN 0009-7322, 2004, Volume 109, Issue 25, pp. 3122 - 3131
The cardiotoxicity of anticancer agents can lead to significant complications that can affect patients being treated for various malignancies. The severity of... 
LONG-TERM SURVIVORS | CARDIAC & CARDIOVASCULAR SYSTEMS | complications | drugs | RETINOIC ACID SYNDROME | chemotherapy | RENAL-CELL CARCINOMA | GROWTH-FACTOR RECEPTOR | PHASE-II TRIAL | HIGH-DOSE CYCLOPHOSPHAMIDE | METASTATIC BREAST-CANCER | PERIPHERAL VASCULAR DISEASE | cardiomyopathy | CONGESTIVE-HEART-FAILURE | MONOCLONAL-ANTIBODIES | HEMATOLOGY | ACUTE PROMYELOCYTIC LEUKEMIA | Anthracyclines - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Antibodies, Monoclonal - adverse effects | Cardiovascular Diseases - therapy | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Radiotherapy - adverse effects | Neoplasms - complications | Antineoplastic Agents - adverse effects | Heart - radiation effects | Neoplasms - radiotherapy | Antineoplastic Agents - classification | Cardiovascular Diseases - diagnosis | Cardiovascular Diseases - etiology | Cytokines - therapeutic use | Risk Factors | Pericardium - radiation effects | Razoxane - therapeutic use | Neoplasms - drug therapy | Radiation Injuries - etiology | Antineoplastic Agents, Alkylating - therapeutic use | Antimetabolites, Antineoplastic - therapeutic use | Biopsy | Antimetabolites, Antineoplastic - adverse effects | Biomarkers | Cardiovascular Diseases - chemically induced | Anthracyclines - therapeutic use | Antineoplastic Agents, Alkylating - adverse effects | Cytokines - adverse effects
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2012, Volume 30, Issue 10, pp. 1042 - 1049
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2007, Volume 25, Issue 5, pp. 493 - 500
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 950 - 961
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2004, Volume 351, Issue 2, pp. 145 - 153
Journal Article